3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
13
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
5
Neoplasms
4
Lung Neoplasms
4
Brain Neoplasms
4
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Skin Diseases
2
Pancreatic Neoplasms
2
Hematologic Neoplasms
2
Uveal Melanoma
1
Spinocerebellar Degenerations
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Soft Tissue Neoplasms
1
Peripheral Nervous System Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Noonan Syndrome 5
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Multiple Myeloma
1
Lymphoma
1
Lymphatic Metastasis
1
Low-grade Serous Ovarian Cancer
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
binimetinib
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts